The Phase III RATIFY trial investigated the addition of midostaurin to 3 + 7 induction chemotherapy in 717 patients with FLT3-mutated AML (555 FLT3-ITD and 162 FLT3-TKD). Here, FLT3 is linked to acute myeloid leukemia.